RxDoctor Payments Data

Andrew Miscovich, PA

Physician Assistant · Seattle, WANPI 1023786431

Payments from drug & device makers

$1,591in general payments, 2019–2025

Across 69 payments — averaging $23.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$544
  • AstraZeneca$375
  • Novo Nordisk$234
  • Boehringer Ingelheim$161
  • Vanda Pharmaceuticals Inc.$115
  • Pfizer$50
  • plus $112 from 3 others

What the payments were for

  • Food & beverage$1,589100%
  • Education$20%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,591 in reported general payments places this provider in the 85th percentile of 2,741 physician assistant providers in Washington.

See all physician assistant providers in Washington

Medicare billing

Part B allowed, 2024
$8,097
Medicare patients
40
Services billed
107

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin71$78,316
TrulicityDulaglutide50$67,958
MounjaroTirzepatide32$45,813
OzempicSemaglutide34$39,887
EliquisApixaban28$26,163
FarxigaDapagliflozin Propanediol13$22,349
RybelsusSemaglutide12$21,356
XareltoRivaroxaban18$17,010
Janumet XrSitagliptin Phos/Metformin Hcl16$15,457
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$8,185
Spiriva HandihalerTiotropium Bromide11$5,961
SymbicortBudesonide/Formoterol Fumarate23$5,236
Lantus SolostarInsulin Glargine,hum.Rec.Anlog21$4,616
Atorvastatin Calcium283$4,549
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog14$4,412

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro, Humulin 70-30$37$115,91594 claims
Boehringer IngelheimJardiance$161$78,31671 claims
Novo NordiskOzempic, Rybelsus$234$61,24346 claims
AstraZenecaFarxiga, Symbicort$375$27,58536 claims
PfizerEliquis$50$26,16328 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,741 physician assistant providers in Washington.

Other physician assistant in Seattle

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →